United States
Faeth Therapeutics, founded in 2019, is pioneering the application of metabolism to combat cancer. Positioned at the intersection of Biotechnology, Health Care, and Health and Wellness, Faeth Therapeutics aims to harness the essential role of metabolism in human biology to address the complex challenges of cancer treatment.
The company's slogan, "Unlocking the power of metabolism to treat cancer," encapsulates its innovative approach and speaks to its potential for significant impact within the industry. Faeth's vision taps into the largely unexplored metabolic processes that are critical to both the survival and growth of cancer cells.
Headquartered in the United States, Faeth Therapeutics secured a substantial $47.00M Series A investment on 30 June 2022, signaling strong investor confidence. This round saw participation from a notable roster of investors including AgFunder, Future Ventures, KdT Ventures, Khosla Ventures, S2G Ventures, Digitalis Ventures, Atacama Ventures, and Cantos. The backing by such diverse venture partners underscores the promise that the company holds within the burgeoning field of metabolic oncology.
